BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kirou KA, Dall`era M, Aranow C, Anders H. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol 2022;13:980079. [DOI: 10.3389/fimmu.2022.980079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Kimura T, Ikeuchi H, Yoshino M, Sakate R, Maruyama S, Narita I, Hiromura K. Profiling of kidney involvement in systemic lupus erythematosus by deep learning using the National Database of Designated Incurable Diseases of Japan. Clin Exp Nephrol 2023. [PMID: 36929044 DOI: 10.1007/s10157-023-02337-x] [Reference Citation Analysis]
2 Dernoncourt A, Liabeuf S, Bennis Y, Masmoudi K, Bodeau S, Laville S, Hurtel-Lemaire AS, Gras-Champel V, Batteux B. Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase(®)). BioDrugs 2023;37:73-87. [PMID: 36401769 DOI: 10.1007/s40259-022-00564-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Raftopoulou S, Rapti A, Karathanasis D, Evangelopoulos ME, Mavragani CP. The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1026449] [Reference Citation Analysis]